Strong Revenue Growth and Strategic Advances Across Key Segments, Enhances Commitment to ESG and Sustainable Development  Impressive Financial Growth: The group reported a 43.5% increase in revenue, driven by a 156% boost in cell therapy revenue and a 75.4% rise in gross profit, showcasing strong performance across key segments. Focused on Innovation and Efficiency: Investing heavily in R&D and market expansion, aiming to drive sustainable growth, enhance global presence, and continue its leadership in technology and ESG practices. Strong ESG Commitment: Joined the UNGC and ranked in the top 35% in EcoVadis' sustainability ratings. It's also committed to science-based climate targets and holds international certifications for environmental and data security management. PISCATAWAY, N.J., Aug. 9, 2024 /PRNewswire/ -- GenScript Biotech Corporation (HKEX: 1548.HK), a leading global technology and service provider of life science R&D and manufacture, today reported its first half 2024 financial results for the six months ended June 30, showcasing impressive revenue growth, significant improvements in gross profit, and strategic advances across its business segments. GenScript is also deepening its commitment to environmental, social, and governance (ESG) practices, marking a significant step towards sustainable development. Sherry Shao, GenScript's rotating CEO, said, "In the first half of 2024, the Group showcased strong market adaptability and growth potential. With a diversified business strategy, exceptional innovation, and efficient operations, GenScript not only maintained solid profitability in the life sciences sector but also saw promising growth in cell therapy product sales. Our subsidiary, Bestzyme, has also outperformed the industry, thanks to years of hard work from the team. While the CDMO sector has been under pressure due to current investment challenges, we're starting to see signs of recovery. We're ready to accelerate our business in the second half of the year. GenScript will continue to strengthen its core competencies across all business lines and foster synergies across divisions to achieve shared growth with our global partners." Strong Financial Performance During the Reporting Period, GenScript generated revenue of approximately ...